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Abstract
Purpose The impact of weight loss on obesity-related colo-
rectal cancer (CRC) risk is not well defined. Previous studies
have suggested that Roux-en-Y gastric bypass (RYGB) sur-
gery may have an unexpected adverse impact on CRC risk.
This study aimed to investigate the impact of RYGB on bio-
markers of CRC risk.
Materials and methods Rectal mucosal biopsies and blood
were obtained from patients undergoing RYGB (n = 22) and
non-obese control participants (n = 20) at baseline and at a
median of 6.5 months after surgery. Markers of systemic in-
flammation and glucose homeostasis were measured.
Expression of pro-inflammatory genes and proto-oncogenes
in the rectal mucosa was quantified using qPCR. Crypt cell
proliferation state of the rectal mucosa was assessed by
counting mitotic figures in whole micro-dissected crypts.
Results At 6.5 months post-surgery, participants had lost
29 kg body mass and showed improvements in markers of
glucose homeostasis and in systemic inflammation.
Expression of pro-inflammatory genes in the rectal mucosa
did not increase and COX-1 expression fell significantly
(P = 0.019). The mean number of mitoses per crypt decreased
from 6.5 to 4.3 (P = 0.028) after RYGB.
Conclusion RYGB in obese adults led to lower rectal crypt cell
proliferation, reduced systemic and mucosal markers of inflam-
mation and improvements in glucose regulation. These consis-
tent findings of reduced markers of tumourigenic potential sug-
gest that surgically induced weight loss may lower CRC risk.
Keywords Bariatric surgery . Gastric bypass . Obesity .
Colorectal cancer . Proliferation
Introduction
Obesity is a well-established risk factor for colorectal cancer
(CRC) [1]. Obese individuals are estimated to have a 33%
higher risk of CRC compared with those with a normal body
mass index (BMI) [2]. Excess adiposity is also a significant
risk factor for colorectal adenoma (CRA) [3], suggesting that
it plays a role in the early stages of CRC development.
There are several plausible mechanisms through which
body fatness could increase CRC risk, which have been
reviewed in detail elsewhere [4]. Obese individuals exhibit a
state of chronic low-grade systemic inflammation [5]. Chronic
inflammation of the colorectal mucosa in individuals with
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inflammatory bowel disease increases CRC risk [6].
Inflammation may contribute to CRC development through
increased genomic damage [7]. Furthermore, obesity leads
to insulin resistance and the resultant hyperinsulinaemia is
associated with increased CRC risk [8].
Bariatric surgery can result in dramatic weight loss, espe-
cially in the short to medium term [9]. In addition, obesity-
related systemic inflammation improves after bariatric surgery
[10, 11] and most patients achieve a reversal of insulin resis-
tance [12]. However, the impact of intentional weight loss on
subsequent CRC risk is poorly understood. To date, there have
been only four observational studies that have reported the
effects of bariatric surgery on subsequent CRC incidence
[13–16]. Pooled analysis of data from these studies shows that
bariatric surgery is associated with a significantly (P = 0.004)
lower CRC incidence (RR 0.73, 95% CI: 0.58–0.90) [17].
However, some investigations of surrogate biomarkers of
CRC risk following bariatric surgery suggest that the opposite
may be true, at least for some types of bariatric surgery.
Sainsbury et al. studied obese patients who underwent
Roux-en-Y gastric bypass (RYGB) surgery and normal BMI
controls [10]. Rectal biopsy samples were collected before
and 6 months after surgery. Before surgery, the obese patients
had a higher rectal epithelial cell mitosis count (increased by
73%, P < 0.01), higher crypt area (increased by 36%,
P < 0.01) and crypt branching was more than twice as com-
mon when compared with controls. These changes are asso-
ciated with higher CRC risk and are some the earliest changes
seen in humans predisposed to gastrointestinal cancer [18].
However, unexpectedly, after RYGB with the resultant signif-
icant weight loss, there was a further increase in mitosis (75%
higher than pre-surgery, P = 0.001) and a decrease in apopto-
sis (P = 0.033). This was accompanied by a greater expression
of pro-inflammatory genes (COX-1, COX-2 and IL-6) at the
mRNA level within the rectal mucosa. The authors concluded
that the hyper-proliferative state after RYGB may be associ-
ated with an increased long-term risk of CRC [10].
Importantly, follow-up of the same RYGB patients at 3 years
showed sustained elevation of rectal epithelial cell prolifera-
tion and crypt size and raised expression of the pro-
tumorigenic cytokine macrophage migration inhibitory factor
(MIF) in the mucosa [19]. A plausible mechanistic case was
made that ‘malabsorptive’ bariatric surgery such as RYGB
could have adverse effects on the colorectal epithelium and,
therefore, on CRC risk because of the diversion into the colon
of damaging luminal content [10]. Such an effect would not be
anticipated with ‘restrictive’ bariatric surgery, where the nor-
mal processes of small bowel digestion and absorption are
largely unaffected. This hypothesis is supported by the finding
that the sleeve gastrectomy (SG) does not lead to increased
mucosal biomarkers of CRC risk [20].
The overall aim of this project was to assess the impact of
RYGB on biomarkers of CRC risk. Specifically, we tested the
hypothesis that surgically induced weight loss results in lower
rectal mucosal crypt cell proliferation, reflecting an overall
reduction in CRC risk.
Materials and Methods
Recruitment
Bariatric Surgery Patients
We recruited adults (18–65 years old) listed for bariatric sur-
gery at a single centre (North Tyneside General Hospital, UK)
fromNovember 2013 to November 2014. All patients listed for
a bariatric surgery during this period were approached by the
research team after their pre-operative clinic visit (Fig. 1). All
bariatric surgery candidates had to complete a 12-week multi-
disciplinary weight management programme and to achieve at
least 5% body weight reduction. Exclusion criteria included:
previous bariatric surgery (n = 5), oral anticoagulation (n = 2)
and use of immunosuppressive therapy (n = 1). Patients who
had a SG (n = 6) or an intra-gastric balloon inserted (n = 3) were
excluded from this analysis. RYGB involved laparoscopic for-
mation of a 50-ml gastric pouch with a 100–150 cm alimentary
limb and 60–75 cm biliopancreatic limb. None of the partici-
pants had a concurrent cholecystectomy.
Non-obese Control Participants
Non-obese (BMI < 30 kg/m2) patients who had either a flex-
ible sigmoidoscopy or colonoscopy within the past year which
did not show any significant colorectal pathology (CRC, CRA
or active inflammation) were invited to take part at least
1 month after their endoscopic examination to allow washout
of the effects of bowel preparation. We also used rectal biop-
sies from eight healthy non-obese participants at baseline from
a previous dietary intervention study (DISC study www.
clinicaltrials.gov/NCT01214681) who were recruited from
the same gastroenterology clinics and using identical biopsy
protocols [21].
Study Design
The participants’ journey and study visits are detailed in
(Supplementary Fig. 1). Bariatric surgery and control partici-
pants had assessment and sample collection at baseline. The
bariatric surgery patients were invited for follow-up at around
6 months post-surgery.
Anthropometry
Demographic data, as well as medical history and current
medications, were recorded during a face-to-face interview
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with a researcher (SA) in a hospital setting and supplemented
by a review of medical records. Anthropometric measure-
ments, including height, weight, waist and hip circumference,
were made using a standardised protocol by a single observer
(SA) at the time patients were listed for surgery. Percentage
body fat was estimated using bioimpedance scales (Tanita
TBF-300MA body composition analyser).
Systemic Markers
Venepuncture was performed after a standardised 6 hour fast.
Blood was collected in BD Vacutainer Plus plastic serum
tubes and centrifuged at 3100 g for 5 minutes within 20 mi-
nutes of collection. Serum was aspirated, frozen immediately
and stored at –80 °C for subsequent batch analysis. Plasma
from a potassium oxalate/sodium fluoride-containing tube
was collected for fasting glucose measurement using the oxi-
dase method. High sensitivity C-reactive protein (hsCRP) was
quantified on an autoanalyser (Roche-Hitachi Modular P,
Roche Diagnostics, Germany). Serum insulin and leptin were
measured using multiplex assay kit (K15164C-1, MSD,
USA). High-performance liquid chromatography (Tosoh
HLC-723G8 glycohaemoglobin analyser, Tosoh Bioscience)
was used for quantification of Haemoglobin A1c (HbA1c).
Homeostasis model assessment-insulin resistance (HOMA-
IR) was calculated using the HOMA2 calculator v2.2.3 [22].
Rectal Mucosal Biopsies
No bowel preparation was used prior to taking rectal biopsies,
because both oral and enema bowel preparation has been
shown to have a significant impact on crypt cell proliferation
in the rectal mucosa [23, 24]. Macroscopically normal rectal
mucosa at a distance of 10 cm from the anal verge was
biopsied. One biopsy was fixed in 10% formalin and exam-
ined by a histopathologist; one in Carnoy’s solution (70%
ethanol, 30% acetic acid) for a minimum of 2 h, then trans-
ferred to 70% ethanol and stored at 4 °C for subsequent crypt
cell proliferation state (CCPS) analysis; one in RNAlater so-
lution (Ambion, Texas, USA) and stored at −80 °C for gene
expression analysis.
Crypt Cell Proliferation State
CCPS was assessed by counting the number of mitoses per
crypt after whole crypt microdissection (WCMD) [25].
Increased proliferation in the basal part of the crypt and ex-
pansion of this proliferative compartment to the upper parts of
the crypt are some of the earliest changes seen in humans
predisposed to gastrointestinal cancer [18]. All samples used
for this analysis were re-labelled and the assessor was blinded
to the identity of each sample. Carnoy’s fixed rectal biopsies
were rehydrated and stained using Schiff’s reagent before
WCMDwas performed as described [18], using a microscope
(Olympus SZ40) at ×25 magnification.
Ten randomly selected non-branching dissected crypts
were analysed for each biopsy. A compound microscope
(Olympus BX51) was used to examine the slides at ×40 mag-
nification with a calibrated eyepiece graticule to make mea-
surements. Crypt area was estimated, based on the assumption
of cylindrical shape. Mitotic figures were identified by focus-
ing through all the layers of the crypt. Cells in late prophase,
metaphase, anaphase and early telophase were recorded as
mitotic. Crypts were divided into ten equal length compart-
ments and the number of mitotic figures in each compartment
was recorded for each of the ten crypts examined. The pres-
ence of at least one branching or bifid crypt was recorded.
Assessments were carried out by two assessors (SA
and FM). Ten samples were randomly selected for the
reproducibility analysis with each of the ten crypts per
sample analysed in tandem. Intra-class correlation coeffi-
cient (ICC) analysis showed excellent agreement between
the two raters (mitoses per crypt count ICC 0.99, 95% CI
0.95–0.99, P < 0.001; crypt length ICC 0.97, 95% CI
0.87–0.99, P < 0.001; crypt width ICC 0.98 0.95 to
0.99, P < 0.001). In addition, assessors quantified CCPS
Fig. 1 Flow of participants through the study
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and crypt dimensions for both pre- and post-surgery for
any individual study participant.
Expression of Pro-inflammatory Genes
and Proto-oncogenes
RNA was extracted from rectal biopsies using the Qiagen
miRNeasy mini kit (Qiagen, UK). Concentration and purity
of RNAwere checked using the NanoDrop 1000 spectropho-
tometer (Thermo Scientific) and integrity using agarose gel
electrophoresis. cDNA was synthesised using the RT2 First
Strand kit (Qiagen, UK). RT2 primer assays and SYBR
Green ROX qPCR Mastermix (Qiagen, UK) were used to
quantify expression of the pro-inflammatory genes IL-6,
MIF, COX-1 and -2 and the proto-oncogenes c-FOS and c-
JUN at the mRNA level using the Applied Biosystems®
StepOnePlus™ real-time PCR machine. Expression was
quantified using the delta Ct approach with GAPDH and
18S rRNA used as reference genes [26].
Statistical Analysis
Statistical analysis was carried out using SPSS software
(Version 22.0 for Windows, SPSS, Chicago, USA). Data are
reported as mean ± standard error or median and interquartile
range (IQR) for normally and non-normally distributed data,
respectively. Paired sample or independent sample t tests were
used to analyse normally distributed data, as appropriate. For
non-normally distributed data, Wilcoxon signed-rank and
Mann-Whitney tests were used, as appropriate. Cross-
tabulation was carried out using Fisher’s exact test or
McNemar’s test for dichotomous variables. Statistical signifi-
cance was set at P < 0.05.
Results
Twenty-three RYGB patients eligible for follow-up
attended a study visit at a median of 6.5 months (range
5.8 to 7.8) after surgery. One of these participants had
significant post-operative complications after a RYGB
with an anastomotic leak requiring total parenteral nutri-
tion and was therefore excluded from this analysis.
Participant characteristics, anthropometry and clinical out-
comes are shown in Table 1.
At baseline, the obese and non-obese groups were well
matched with no differences in age, sex, NSAID use and
previous cholecystectomy rates. However, none of the
obese pre-surgery participants reported being current
smokers whilst 30% of the non-obese control participants
reported being current smokers (daily/occasional). Non-
smoking was a strict selection criterion by the clinical
team for bariatric surgery candidates. As anticipated, all
measures of body fatness were significantly higher for
obese compared with non-obese participants. At
6.5 months post-surgery, participants had lost 29 kg body
mass, the majority of which (mean 23 kg) was body fat.
Systemic Markers Indicate Improvements
in Inflammation and Insulin Resistance After Bariatric
Surgery
Pre-surgery, mean serum hsCRP concentration was higher,
but not significantly so, in the obese group compared with
the non-obese controls (Table 2). Following surgically in-
duced weight loss, hsCRP concentration fell by 71%
(P < 0.001). As expected [27], fasting glucose and serum
insulin, leptin and HOMA-IR were all significantly elevated
in the obese group pre-surgery compared with non-obese con-
trols, although the difference in HbA1c and did not reach
statistical significance (Table 2). At baseline, serum leptin
concentration was nearly six times higher in obese patients
compared with non-obese controls and decreased significantly
after bariatric surgery (Table 2). Moreover, surgically induced
weight loss resulted in significant improvements in all mea-
sured markers of glucose homeostasis (Table 2).
Expression of Pro-inflammatory Genes
and Proto-oncogenes in the Rectal Mucosa After Bariatric
Surgery
There was no evidence of macroscopic inflammation of the
rectal mucosa in any of the participants and none of the rectal
biopsies showed evidence of microscopic colitis when exam-
ined by a consultant histopathologist. At baseline, rectal mu-
cosal expression of the pro-inflammatory genes, COX-1,
COX-2, IL-6 and MIF, was similar in both obese and non-
obese groups (Table 3). After bariatric surgery,COX-1 expres-
sion in rectal biopsies fell significantly (P = 0.019) but there
was no change in expression of COX-2, IL-6 and MIF
(Table 3). There were no differences in expression of the
proto-oncogenes c-FOS and c-JUN between non-obese and
obese participants and no changes following bariatric surgery
in the obese (Table 3).
Rectal Crypt Cell Proliferation Decreases After Bariatric
Surgery with Concomitant Changes in Distribution
of Mitotic Figures
Crypt cell kinetics and crypt area were similar in obese pa-
tients at baseline and in non-obese participants (Table 4 and
Fig. 2a–c). However, after bariatric surgery, the mean number
of mitoses per crypt decreased significantly (34% decrease)
and the proportion of mitoses in top half of the crypt fell by
35% (Fig. 2a, b). Despite these substantial changes in mea-
sures of cell proliferation, there was no significant change in
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crypt area after surgery (Fig. 2c). There was also no significant
difference in the number of participants in whom branching
crypts were detected; two patients had branching crypts pre-
surgery and five post-surgery (P = 0.375).
Discussion
Our main findings were a 34% decrease in the mean number
of mitoses per crypt and a contraction of the crypt proliferative
compartment at 6.5 months after RYGB. These changes were
associated with dramatic improvements in systemic markers
of glucose homeostasis and inflammation. There was also a
decrease in expression of the pro-inflammatory gene COX-1
in the rectal mucosa. Furthermore, there were no significant
changes in the expression of pro-tumourogenic (MIF, c-FOS
and c-JUN) or pro-inflammatory genes (COX-2 and IL-6) in
the rectal mucosa. Together, these observations suggest that
surgically induced weight loss may reduce obesity-related risk
of CRC.
Findings in the Context of Other Studies
Does Obesity Alter Crypt Cell Proliferation in the Human
Colorectum?
There is paucity of research on the impact of obesity on CCPS
in humans but the limited evidence available suggests a higher
proliferation state in the rectal mucosa of obese comparedwith
normal BMI individuals [10, 28]. On this basis, the lack of a
difference in CCPS measures between obese and non-obese
individuals in our study is unexpected but may be due to the
fact that the BMI of our obese patients was considerably lower
than that reported by previous studies in this field [10, 28].
Table 1 Participant
characteristics at baseline and
post-RYGB
Non-obese
control
(N = 20)
Obese pre-
surgery
(N = 22)
Obese post-
surgery
(N = 22)
P value control
vs. pre-surgery
P value pre-
vs. post-sur-
gery
Age (years)* 46.0 (2.6) 47.0 (1.2) – 0.720 –
Sex—N (%)
female
12 (60) 4 (18) – 0.175† –
Smoking—N (%)
Daily 5 (25) 0 1 (5) 0.002† < 0.001‡
Occasional 1 (5) 0 11 (52)
Ex-smoker 2 (10) 11 (50) 9 (43)
Never smoked 12 (60) 10 (45) 0
Missing data 0 1 (4) 0
NSAID use—N
(%)
5 (25) 10 (45) 1 (5) 0.209† 0.004§
Previous
cholecystecto-
my—N (%)
2 (10) 4 (18) – 0.665† –
Weight (kg)* 71.8 (2.8) 114.8 (3.7) 86.3 (3.5) < 0.001 < 0.001
BMI (kg/m2)* 25.4 (0.5) 42.4 (1.4) 31.3 (1.2) < 0.001 < 0.001
Body fat (%)* 30.3 (1.3) 47.6 (1.0) 36.1 (1.5) < 0.001 < 0.001
Waist (cm)*
Men 95.9 (2.9) 137.3 (2.0) 112.5 (4.5) < 0.001 0.007
Women 83.4 (2.2) 117.5 (2.2) 91.9 (3.5) < 0.001 < 0.001
Waist to hip ratio*
Men 0.93 (0.01) 1.07 (0.03) 0.99 (0.03) 0.001 0.067
Women 0.82 (0.02) 0.89 (0.01) 0.84 (0.02) 0.010 0.007
Independent sample t test used to compare non-obese control and obese pre-surgery participants, unless otherwise
indicated. Paired sample t test used to compare participants pre- and post-surgery, unless otherwise indicated
NSAID non-steroidal anti-inflammatory agent
*Values indicate mean (SEM)
†Fisher’s exact test
‡Wilcoxon sign test
§Related sample McNemar test
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The inclusion of smokers in the non-obese control group may
also have been contributing factor. However, a sensitivity
analysis excluding smokers from the non-obese control group
did not result in any significant difference in CCPS measures
between obese and non-obese groups. Also, smoking status
was not a significant factor in the expression of any of the
genes of interest (Kruskal-Wallis test).
Effects of Bariatric Surgery on Rectal Crypt Cell Proliferation
Sainsbury et al. found a significantly higher number of mito-
ses per crypt in the rectum of patients 6 months after RYGB
compared with baseline [10]. In contrast, a similar study by
Kant et al., from the same laboratory, found no significant
change in rectal mucosal CCPS 6months after a SG compared
with baseline [28]. Key characteristics of the participants in,
and findings from, these two studies and from the present
study are summarised in Table 5.
Although many aspects of the study design used by
Sainsbury et al. [10] and in the present study were similar,
there are several key features of the patient population and
of the surgical procedures which differed between the studies
and which may have contributed to contrasting outcomes.
First, the pre-surgery mean BMI of the patients studied by
Sainsbury et al. was 12 kg/m2 higher than that of our patients.
The mean post-surgery BMI of Sainsbury’s patients was sim-
ilar to the pre-surgery BMI of our patients. However, more
pertinently, in the Sainsbury et al. study, RYGB procedures
were performed with longer limb lengths (roux limb 150 cm,
BP limb 150 cm) than in the present study. BP limbs of
150 cm are significantly longer than usual current surgical
practice. The most recent National Bariatric Surgery
Registry (NBSR) report [29] of bariatric procedures per-
formed in the UK and Ireland shows that the vast majority
of RYGB procedures were carried out with a BP limb length
of ≤ 100 cm and only 3.8% had a BP limb of 150 cm. Longer
roux and BP limbs have been associated with an increase in
malabsorptive complications, including an increase in diar-
rhoea [30, 31]. In this study cohort, we have previously re-
ported that diarrhoea, a common symptom of malabsorption,
was rare post-surgery [32]. Therefore, we propose that the
limb lengths used in the present study are unlikely to cause
significant malabsorption [32]. We hypothesise that longer
bypass limbs are more likely to cause hyper-proliferation
through malabsorption and exposure of the colorectum to
Table 2 Systemic markers of
inflammation, glucose
homeostasis and adiposity
Marker Non-obese
control
(N = 12)
Obese pre-
surgery
(N = 22)
Obese post-
surgery
(N = 22)
P value control
vs. pre-surgery
P value pre- vs.
post-surgery
hsCRP
(mg/L)
3.6 (1.2) 5.5 (0.9) 1.6 (0.4) 0.190 < 0.001
Fasting
glucose
(mmol/L)
4.5 (0.1) 5.8 (0.4) 4.9 (0.4) 0.003 0.001
HbA1c
(mmol/-
mol)
36.1 (0.9) 42.2 (2.9) 38.5 (2.4) 0.194 0.001
Insulin
(pmol/L)
64.6 (10.6) 117.1 (19.6) 54.3 (7.8) 0.025 0.001
HOMA-IR 1.2 (0.2) 2.2 (0.3) 1.0 (0.1) 0.014 < 0.001
Leptin
(ng/mL)
11.2 (3.2) 62.5 (14.3) 15.6 (3.9) 0.002 0.003
Data are presented as mean (SEM). Independent sample t test used to compare non-obese control and obese pre-
surgery participants. Paired sample t test used to compare participants pre- and post-surgery
hsCRP highly sensitive C-reactive protein,HbA1c haemoglobin A1c, HOMA-IR homeostasis model assessment-
insulin resistance
Table 3 Expression of pro-inflammatory genes in rectal biopsies from
non-obese control participants and obese participants pre- and post-
RYGB
Gene Non-obese
control
(N = 20)
Obese pre-
surgery
(N = 22)
Obese Post-
surgery
(N = 22)
P value
control
vs. pre-
surgery
P value
pre- vs.
post-
surgery
MIF 2.162 (2.375) 1.796 (1.085) 2.239 (1.269) 0.497 0.322
COX-1 0.038 (0.021) 0.042 (0.029) 0.031 (0.015) 0.420 0.019
COX-2 0.012 (0.089) 0.009 (0.004) 0.010 (0.008) 0.676 0.931
IL-6 0.007 (0.037) 0.003 (0.005) 0.006 (0.010) 0.068 0.322
c-FOS 0.187 (0.230) 0.128 (0.321) 0.169 (0.665) 0.548 0.306
c-JUN 0.097 (0.109) 0.105 (0.057) 0.101 (0.096) 0.450 0.638
Data are expressed as median (IQR) 2-ΔCT × 1000 relative to geometric
mean of reference genes GAPDH and 18S rRNA. Mann-Whitney U test
used to compare non-obese control and obese pre-surgery participants.
Wilcoxon signed-rank test used to compare participants pre- and post-
surgery
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harmful luminal content. This hypothesis is supported by the
increase in rectal mucosal expression of pro-inflammatory
genes (COX-1, COX-2 and IL-6) in the Sainsbury et al. study,
which is in stark contrast with the present study, as well as the
SG study by Kant et al. (Table 5).
Another notable difference between studies is the perfor-
mance of concurrent cholecystectomy in almost half of the
patients in the study by Sainsbury and colleagues (Table 5).
Others have shown that the mitotic index of colonic mucosa
(biopsies collected 20 cm from the anal orifice) increased by
approximately 50% at 6 months after cholecystectomy [33],
and cholecystectomy has been associated with increased CRC
risk [34–36]. Faecal secondary bile acids, associated with both
increased cell proliferation and increased CRC risk, are also
raised after cholecystectomy [37, 38].
The Effects of Weight Loss Through Lifestyle Intervention
on Rectal Crypt Cell Proliferation
Using autoradiography after incubation of tissue with 3H-thy-
midine, Steinbach et al. measured rectal mucosal cell prolifer-
ation before and after a 16-week weight loss intervention with
caloric restriction in a group of adults with initial mean BMI
38 kg/m2 [39]. This intervention produced a fall of 8.6% in
body weight, 39% lower whole crypt labelling index and 57%
reduction in upper crypt labelling. These changes in rectal cell
kinetics are similar to our observations, despite a more modest
degree of weight loss in the lifestyle intervention study.
Potential Mechanisms for the Beneficial Effects of Weight
Loss on CRC Risk
Improvement in Hyperinsulinaemia Obesity is strongly as-
sociated with hyperinsulinaemia which is mechanistically
linked to CRC [4]. Hyperinsulinaemia increases the bioavail-
ability of circulating insulin-like growth factor-1 (IGF-1) by
inhibiting production of IGF-binding proteins [4]. IGF-1
binds to the IGF-1 receptor, which is expressed in normal
colonic tissue [40], and induces a signalling cascade which
leads to cell growth, proliferation and inhibition of apoptosis
[41]. We propose that the improvements in hyperinsulinaemia
after surgically induced weight loss (Table 2) may contribute
to the changes in CCPS we observed after bariatric surgery.
Reduced Systemic and Gut InflammationWe found signif-
icant improvement in the obesity-related low-grade systemic
inflammatory state post-surgery (Table 3). Furthermore,COX-
1 expression in the rectal mucosa was reduced significantly
with no significant change in the expression of other pro-
inflammatory genes (MIF, COX-2 and IL-6). Importantly,
the use of NSAID medication was less frequent post-surgery
(Table 1), which makes it unlikely that NSAID use was a
confounder.
Others have shown that 10% weight loss induced by a
very-low-calorie diet reduced circulating concentrations of in-
flammatory cytokines (TNF-α, IL-1β, IL-8 and MCP-1) by
25–57% in rectosigmoid biopsies and reduced Tcell and mac-
rophage counts [42]. Faecal calprotectin (FCP), an established
marker of whole gut inflammation, is positively correlated
with obesity, as well as with other lifestyle factors associated
with CRC risk [43]. One fifth of overweight/obese individuals
enrolled in a weight loss programme (Slimming World) had a
high FCP (> 50 μg/g) at baseline and, in these individuals,
FCP reduced during the study period [44]. These studies are in
keeping with the hypothesis that weight loss in overweight/
obese individuals reduces both systemic and gut inflamma-
tion. Given that inflammation is an enabling characteristic in
tumorigenesis [45], it is plausible that reducing inflammation
through weight loss may reduce CRC risk.
Exposure to Bile Acids Bariatric surgery, especially the
RYGB, disrupts the enterohepatic bile circulation. A sys-
tematic review found seven studies reporting on the ef-
fects of RYGB on fasting systemic bile acids (BAs), six
Table 4 Rectal mucosal crypt
cell proliferation state and crypt
dimensions
Non-obese
control
(N = 20)
Obese pre-
surgery
(N = 22)
Obese post-
surgery
(N = 22)
P value control
vs. pre-surgery
P value pre-
vs. post-sur-
gery
Total mitoses per
crypt
5.9 (1.0) 6.5 (0.9) 4.3 (0.5) 0.640 0.028
Mitoses in top half
of the crypt (%)
6.7 (1.5) 9.1 (1.7) 5.9 (1.2) 0.199 0.047
Crypt length (mm) 0.53 (0.01) 0.53 (0.02) 0.55 (0.01) 0.591 0.448
Crypt width (mm) 0.12 (0.003) 0.11 (0.004) 0.12 (0.002) 0.360 0.212
Crypt area (mm2) 0.21 (0.01) 0.20 (0.01) 0.21 (0.01) 0.786 0.282
Data are presented as mean (SEM). Independent sample t test used to compare non-obese control and obese pre-
surgery participants. Paired sample t test used to compare participants pre- and post-surgery
OBES SURG
of which showed higher systemic BAs after RYGB [46].
Th i s i s impo r t an t a s s e rum deoxycho l i c ac id
concentrations are positively correlated with colonic mu-
cosal proliferation [47]. However, little is known about
the impact of modern bariatric procedures on faecal
BAs. Since shortening of effective small bowel and the
resultant intractable diarrhoea are associated with in-
creased concentrations of BAs in the colon [48], it is
likely that bariatric procedures with significant shortening
of small bowel length will have a similar outcome.
Historical context comes from studies of the jejunoileal
bypass (JIB), a procedure popular in 1960/1970s, which in-
duced malabsorption by bypassing more than 90% of the
small bowel and creating a short bowel syndrome. This pro-
cedure led to severe metabolic complications, including diar-
rhoea and life-threatening malnutrition so that up to 33% of
patients who had the procedure had to have a reversal [49].
Several rat studies showed increased CRC in JIB compared
with sham operated controls [50–52]. Importantly, JIB in-
duced hyper-proliferation of the rectal mucosa in humans
[53, 54] and expansion of the proliferative compartment [54]
which were associated with higher concentrations of faecal
BAs and lipids [54, 55].
Strengths and Limitations
The main strength of this study is the use of paired rectal
mucosal tissue in unprepared bowel from the same indi-
viduals before and after RYGB surgery, as well as in non-
obese control participants. The main limitation of this
analysis is the relatively small number of participants,
although this is comparable to other similar studies in
the field (Table 5). Whilst we could detect differences in
CCPS measures from before to after RYGB surgery, we
lacked statistical power to perform potentially interesting
sub-group analysis.
In summary, RYGB in obese adults led to a decrease in
rectal crypt cell proliferation, reduced systemic and mu-
cosal markers of inflammation, as well as improvements
in glucose regulation. These findings suggest that such
surgically induced weight loss may lower CRC risk, in
keeping with the limited evidence of protection against
CRC which has been reported in observational studies
[17]. We hypothesise that RYGB involving longer bypass
limbs may cause hyper-proliferation through malabsorp-
tion and exposure of the colorectum to BAs and, possibly,
other luminal agents. In the absence of significant specific
benefits of ‘long limb’ RYGB and the potential increase
in biomarkers of future CRC risk associated with this
procedure, ‘ long limb’ RYGB surgery should be
approached with caution. Preference should be given to
RYGB procedures with shorter bypass limbs which, in the
present study, were associated with reduced biomarkers of
CRC risk.
Fig. 2 Rectal mucosal crypt cell proliferation status in non-obese control
participants and in obese participants pre- and post-RYGB surgery. a
Mean total number of mitoses per crypt. b Percentage of mitoses in the
upper half of the crypt. cMean crypt area. Dark circles represent mean for
the group and error bars represent standard error. Independent sample t
test used to compare non-obese control and obese pre-surgery partici-
pants. Paired sample t test used to compare obese participants pre- and
post-surgery (*p < 0.05)
OBES SURG
Acknowledgements We thank Dr. Catherine Hobday and Dr. Robert
Stirling, consultant histopathologists at North Tyneside General Hospital,
for their contributions to this study.
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflicts of
interest.
Ethical Statement The study was approved by the Newcastle & North
Tyneside National Research Ethics Service Committee (13/NE/0204).
Consent Statement Informed written consent was obtained from all
participants.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body
mass index and colorectal cancer: findings from 56 observational
studies. Obes Rev. 2010;11(1):19–30.
2. MaY, Yang Y,Wang F, et al. Obesity and risk of colorectal cancer: a
systematic review of prospective studies. PLoS One. 2013;8(1):
e53916.
3. Omata F, Deshpande GA, Ohde S, et al. The association between
obesity and colorectal adenoma: systematic review and meta-anal-
ysis. Scand J Gastroenterol. 2013;48(2):136–46.
4. Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer.
Gut. 2013;62(6):933–47.
5. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity.
Annu Rev Immunol. 2011;29:415–45.
6. Danese S, Malesci A, Vetrano S. Colitis-associated cancer: the dark
side of inflammatory bowel disease. Gut. 2011;60(12):1609–10.
7. Prizment AE, Anderson KE, Visvanathan K, et al. Association of
inflammatory markers with colorectal cancer incidence in the ath-
erosclerosis risk in communities study. Cancer Epidemiol
Biomarkers Prev. 2011;20(2):297–307.
8. Ho GY, Wang T, Gunter MJ, et al. Adipokines linking obesity with
colorectal cancer risk in postmenopausal women. Cancer Res.
2012;72(12):3029–37.
9. Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-
surgical treatment for obesity: a systematic review and meta-
analysis of randomised controlled trials. BMJ. 2013;347:f5934.
10. Sainsbury A, Goodlad RA, Perry SL, et al. Increased colorectal
epithelial cell proliferation and crypt fission associated with obesity
and roux-en-Y gastric bypass. Cancer Epidemiol Biomarkers Prev.
2008;17(6):1401–10.
11. Rao SR. Inflammatory markers and bariatric surgery: a meta-anal-
ysis. Inflamm Res. 2012;61(8):789–807.
12. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabe-
tes after bariatric surgery: systematic review and meta-analysis. Am
J Med. 2009;122(3):248–56. e5
Table 5 Studies of the impact of
bariatric surgery on rectal CCPS
at 6 months post-surgery
Present study
(N = 22)
Sainsbury et al. [10]
(N = 24)
Kant et al. [20]
(N = 23)
Procedures RYGB RYGB SG
BMI (kg/m2)
Baseline 42.4 54.4 65.7
Follow-up 31.3 41.8 50.1
RYGB limb lengths
BP limb 63 150 n/a
Roux limb 127 150 n/a
Concurrent cholecystectomy
(%)
0 46 NR
CRP (mg/l)
Baseline 5.5 8.7 17.5
Follow-up 1.6 3.8 13.5
Gene expression
COX-1 ↓ ↑ ↔
COX-2 ↔ ↑ ↔
IL-6 ↔ ↑ ↔
MIF ↔ ↔ ↑
Mitoses per crypt ↓ ↑ ↔
Mitoses in upper part of crypt ↓ ↑ ↔
Crypt area ↔ ↔ ↔
Branching crypts ↔ ↔ ↔
NR not reported
OBES SURG
13. Christou NV, Lieberman M, Sampalis F, et al. Bariatric surgery
reduces cancer risk in morbidly obese patients. Surg Obes Relat
Dis. 2008;4(6):691–5.
14. Adams TD, Stroup AM, Gress RE, et al. Cancer incidence and mor-
tality after gastric bypass surgery. Obesity. 2009;17(4):796–802.
15. McCawley GM, Ferriss JS, Geffel D, et al. Cancer in obese women:
potential protective impact of bariatric surgery. J Am Coll Surg.
2009;208(6):1093–8.
16. Derogar M, Hull MA, Kant P, et al. Increased risk of colorectal
cancer after obesity surgery. Ann Surg. 2013;258(6):983–8.
17. Afshar S, Kelly SB, Seymour K, et al. The effects of bariatric
surgery on colorectal cancer risk: systematic review and meta-anal-
ysis. Obes Surg. 2014;24(10):1793–9.
18. Wong WM, Mandir N, Goodlad RA, et al. Histogenesis of human
colorectal adenomas and hyperplastic polyps: the role of cell pro-
liferation and crypt fission. Gut. 2002;50(2):212–7.
19. Kant P, Sainsbury A, Reed KR, et al. Rectal epithelial cell mitosis
and expression of macrophage migration inhibitory factor are in-
creased 3 years after Roux-en-Y gastric bypass (RYGB) for morbid
obesity: implications for long-term neoplastic risk following
RYGB. Gut. 2011;60(7):893–901.
20. Kant P, Perry SL, Dexter SP, Race AD, Loadman PM, Hull MA.
Mucosal biomarkers of colorectal cancer risk do not increase at 6
months following sleeve gastrectomy, unlike gastric bypass.
Obesity (Silver Spring, Md). 2013.
21. Malcomson FC, Willis ND, McCallum I, Xie L, Ibero-Baraibar I,
Leung WC, et al. Effects of supplementation with nondigestible
carbohydrates on fecal calprotectin and on epigenetic regulation
of SFRP1 expression in the large-bowel mucosa of healthy individ-
uals. Am J Clin Nutr. 2017;11.
22. HOMA2 calculator: Diabetes Trial Unit. The Oxford Centre for
Diabetes, Endocrinology & Metabolism.; [cited 2016]; Available
from: https://www.dtu.ox.ac.uk/homacalculator/.
23. DrimanDK, Preiksaitis HG. Colorectal inflammation and increased
cell proliferation associated with oral sodium phosphate bowel
preparation solution. Hum Pathol. 1998;29(9):972–8.
24. Lehy T, Abitbol JL, Mignon M. Influence of rectal preparation by
enema on cell proliferation in the normal rectal mucosa in man.
Gastroenterol Clin Biol. 1984;8(3):216–21.
25. Mills SJ, Mathers JC, Chapman PD, et al. Colonic crypt cell pro-
liferation state assessed by whole crypt microdissection in sporadic
neoplasia and familial adenomatous polyposis. Gut. 2001;48(1):
41–6.
26. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: min-
imum information for publication of quantitative real-time PCR
experiments. Clin Chem. 2009;55(4):611–22.
27. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest.
2000;106(4):473–81.
28. Kant P, Perry SL, Dexter SP, et al.Mucosal biomarkers of colorectal
cancer risk do not increase at 6 months following sleeve gastrecto-
my, unlike gastric bypass. Obesity (Silver Spring, Md). 2014;22(1):
202–10.
29. NBSR. The 2014 National Bariatric Surgery Register report. 2014.
30. Freeman JB, Kotlarewsky M, Phoenix C. Weight loss after extend-
ed gastric bypass. Obes Surg. 1997;7(4):337–44.
31. Potoczna N, Harfmann S, Steffen R, et al. Bowel habits after bar-
iatric surgery. Obes Surg. 2008;18(10):1287–96.
32. Afshar S, Kelly SB, Seymour K, Woodcock S, Werner AD,
Mathers JC. The effects of bariatric procedures on bowel habit.
Obes Surg. 2016.
33. Bandettini L, Filipponi F, Romagnoli P. Increase of the mitotic
index of colonic mucosa after cholecystectomy. Cancer.
1986;58(3):685–7.
34. Nogueira L, Freedman ND, Engels EA, et al. Gallstones, cholecys-
tectomy, and risk of digestive system cancers. Am J Epidemiol.
2014;179(6):731–9.
35. Lee SS, Cha S, Lee RL. The relationship between cholecystectomy
and colon cancer: an Iowa study. J Surg Oncol. 1989;41(2):81–5.
36. Shao T, Yang YX. Cholecystectomy and the risk of colorectal can-
cer. Am J Gastroenterol. 2005;100(8):1813–20.
37. Breuer NF, Jaekel S, Dommes P, et al. Fecal bile acid excretion
pattern in cholecystectomized patients. Dig Dis Sci. 1986;31(9):
953–60.
38. Arlow FL, Dekovich AA, Priest RJ, et al. Bile acid—mediated
postcholecystectomy diarrhea. Arch Intern Med. 1987;147(7):
1327–9.
39. Steinbach G, Heymsfield S, Olansen NE, et al. Effect of caloric
restriction on colonic proliferation in obese persons: implications
for colon cancer prevention. Cancer Res. 1994;54(5):1194–7.
40. Freier S, Weiss O, Eran M, et al. Expression of the insulin-like
growth factors and their receptors in adenocarcinoma of the colon.
Gut. 1999;44(5):704–8.
41. Sridhar SS, Goodwin PJ. Insulin-insulin-like growth factor axis and
colon cancer. J Clin Oncol. 2009;27(2):165–7.
42. Pendyala S, Neff LM, Suarez-Farinas M, et al. Diet-induced weight
loss reduces colorectal inflammation: implications for colorectal
carcinogenesis. Am J Clin Nutr. 2011;93(2):234–42.
43. Poullis A, Foster R, Shetty A, et al. Bowel inflammation as mea-
sured by fecal calprotectin: a link between lifestyle factors and
colorectal cancer risk. Cancer Epidemiol Biomarkers Prev.
2004;13(2):279–84.
44. Kant P, Fazakerley R, Hull MA. Faecal calprotectin levels before
and after weight loss in obese and overweight subjects. Int J Obes.
2013;37(2):317–9.
45. Hanahan D, Weinberg RA. Hallmarks of cancer: the next genera-
tion. Cell. 2011;144(5):646–74.
46. Cole AJ, Teigen LM, Jahansouz C, et al. The influence of bariatric
surgery on serum bile acids in humans and potential metabolic and
hormonal implications: a systematic review. Curr Obes Rep.
2015;4(4):441–50.
47. Ochsenkuhn T, Bayerdorffer E, Meining A, et al. Colonic mucosal
proliferation is related to serum deoxycholic acid levels. Cancer.
1999;85(8):1664–9.
48. Ohkohchi N, Andoh T, Izumi U, et al. Disorder of bile acid metab-
olism in children with short bowel syndrome. J Gastroenterol.
1997;32(4):472–9.
49. Anderson PE, Pilkington TR, Gazet JC. Reversal of jejunoileal
bypass in patients with morbid obesity. Br J Surg. 1994;81(7):
1015–7.
50. Scudamore CH, Freeman HJ. Effects of small bowel transection,
resection, or bypass in 1,2-dimethylhydrazine-induced rat intestinal
neoplasia. Gastroenterology. 1983;84(4):725–31.
51. Rainey JB, Davies PW, Williamson RC. Relative effects of ileal
resection and bypass on intestinal adaptation and carcinogenesis.
Br J Surg. 1984;71(3):197–202.
52. Bristol JB, Wells M, Williamson RC. Adaptation to jejunoileal
bypass promotes experimental colorectal carcinogenesis. Br J
Surg. 1984;71(2):123–6.
53. Appleton GV, Wheeler EE, Al-Mufti R, et al. Rectal hyperplasia
after jejunoileal bypass for morbid obesity. Gut. 1988;29(11):1544–
8.
54. Steinbach G, Lupton J, Reddy BS, et al. Effect of calcium supple-
mentation on rectal epithelial hyperproliferation in intestinal bypass
subjects. Gastroenterology. 1994;106(5):1162–7.
55. Koivisto P, Miettinen TA. Adaptation of cholesterol and bile acid
metabolism and vitamin B12 absorption in the long-term follow-up
after partial ileal bypass. Gastroenterology. 1986;90(4):984–90.
OBES SURG
